Houttuynia cordata thunb. nose-coating paste, preparation method and application

Abstract

The present application relates to the technical field of traditional Chinese medicine, and particularly relates to a houttuynia cordata coated nose ointment, a preparation method and application. The houttuynia cordata coated nose ointment comprises the following components in percentage by weight: 5-10% of houttuynia cordata extract, 80-90% of a vaseline-lanolin compound base, 1-3% of a penetration enhancer, and 0.1-0.5% of an antioxidant. The mass ratio of vaseline to lanolin in the vaseline-lanolin compound base is 7:3. The present application uses the houttuynia cordata extract as a core effective component, and is prepared by matching the vaseline-lanolin compound base, the penetration enhancer and the antioxidant in a specific proportion to form an external ointment, which can accurately solve the problems of drug resistance, obvious adverse reactions, poor dosage form adaptability and insufficient targeting in the treatment of existing sinusitis.

Description

Technical Field

[0001] This invention relates to the field of traditional Chinese medicine technology, specifically to a houttuynia cordata nasal ointment, its preparation method, and its application. Background Technology

[0002] Sinusitis is a very common inflammatory disease of the nasal and sinus mucosa in clinical practice. Its pathogenesis is complex, often related to multiple factors such as infection, immune dysfunction, and nasal ventilation obstruction. It is characterized by a prolonged course and frequent relapses. After contracting the disease, patients are often persistently troubled by symptoms such as nasal congestion, purulent nasal discharge, headache, and decreased sense of smell, severely affecting their daily work, study, and sleep quality. If the condition is not effectively controlled for a long period, it may also lead to a series of secondary problems such as nasal polyps, intracranial complications of sinusitis, and orbital complications, further damaging the patient's health and increasing the difficulty of clinical treatment. Currently, there are various treatment options for sinusitis in clinical practice, among which antibiotics are a commonly used treatment method. However, long-term or inappropriate use of antibiotics can easily lead to the development of drug-resistant strains, causing a gradual decrease in drug efficacy. Furthermore, it may disrupt the balance of normal nasal flora, causing systemic adverse reactions such as gastrointestinal discomfort, which is detrimental to long-term treatment. While nasal corticosteroids can alleviate mucosal inflammation and edema to some extent, long-term use may cause local irritation to the nasal mucosa, leading to discomfort such as nasal dryness, nosebleeds, and olfactory abnormalities. Some patients have low tolerance and find it difficult to adhere to regular medication, affecting treatment efficacy. Furthermore, traditional Chinese medicine has unique advantages in the treatment of sinusitis. Topical preparations developed based on the theories of clearing heat and detoxifying, and unblocking nasal passages, can alleviate symptoms to some extent. However, most traditional dosage forms, such as decoctions and powders, still have significant shortcomings in dosage form suitability and targeting. The drugs cannot accurately adhere to the lesions on the nasal mucosa, resulting in low penetration efficiency of active ingredients and failure to achieve ideal local drug concentrations, leading to poor efficacy and failing to meet the actual needs of clinical treatment. Therefore, there is an urgent clinical need for a topical preparation that can overcome the shortcomings of existing treatment options, is based on traditional Chinese medicine theory, combines modern pharmaceutical technology, is safe and effective, highly targeted, adapts to the nasal physiological environment, can directly act on the lesions on the nasal mucosa, improve local drug efficacy, and reduce adverse reactions. Summary of the Invention

[0003] The purpose of this invention is to provide a houttuynia cordata nasal ointment, its preparation method, and its application, in order to solve the problems of drug resistance, significant adverse reactions, poor dosage form compatibility, and insufficient targeting in existing sinusitis treatments.

[0004] To achieve the above objectives, the present invention adopts the following technical solution: A houttuynia cordata nasal ointment comprises the following components in weight percentage: 5%~10% houttuynia cordata extract, 80%~90% petrolatum-lanolin composite matrix, 1%~3% penetration enhancer, and 0.1%~0.5% antioxidant; wherein the mass ratio of petrolatum to lanolin in the petrolatum-lanolin composite matrix is ​​7:3.

[0005] Optionally, the active ingredient in the houttuynia cordata extract is calculated as sodium houttuynin.

[0006] Optionally, the penetration enhancer is azone.

[0007] Optionally, the antioxidant is vitamin E.

[0008] A method for preparing houttuynia cordata nasal ointment includes the following steps: S1. Extract and purify the herb Houttuynia cordata to obtain Houttuynia cordata extract; S2. Pulverized oil and lanolin are heated to a molten state to form a composite matrix. The houttuynia cordata extract, penetration enhancer and antioxidant are added. After stirring evenly and cooling, the mixture is ground and refined to obtain a paste. S3. The ointment is packaged and sterilized to obtain the nasal ointment.

[0009] Optionally, in step S1, the extraction and purification include extraction using water extraction and alcohol precipitation, and purification using macroporous resin.

[0010] Optionally, in step S2, the temperature at which the material is heated to a molten state is 50~60℃; the grinding and refining process is carried out using a colloid mill.

[0011] Optionally, in step S3, the sterilization process is ultraviolet sterilization.

[0012] The application of a houttuynia cordata nasal ointment in the preparation of a drug for treating sinusitis.

[0013] Optionally, the nasal ointment is to be applied to the nasal mucosa 3-4 times daily.

[0014] Compared with the prior art, the present invention has the following beneficial effects: This application uses Houttuynia cordata extract as the core active ingredient, combined with a specific ratio of petrolatum-lanolin complex matrix, penetration enhancer, and antioxidant to prepare a topical ointment. This ointment can precisely address the problems of drug resistance, significant adverse reactions, poor dosage form compatibility, and insufficient targeting in existing sinusitis treatments. By combining Houttuynia cordata extract, which has the effects of clearing heat and detoxifying, reducing swelling and draining pus, and opening nasal passages, with a complex matrix adapted to the physiological environment of the nasal cavity, it avoids the adverse reactions that may be caused by systemic medication. Furthermore, the characteristics of the ointment dosage form enable the drug to adhere precisely to the lesion site of the nasal mucosa, prolonging the drug's action time, increasing the local drug concentration, and effectively exerting anti-inflammatory, antibacterial, and mucosal congestion and edema-reducing effects. This provides a safe and effective new option for topical application of traditional Chinese medicine for the treatment of sinusitis. The composite matrix, with petrolatum and lanolin blended in a specific mass ratio, ensures the ointment's excellent spreadability and stability, facilitating application and adhesion to the nasal mucosa while minimizing irritation and enhancing user comfort, thus adapting to the nasal physiological environment. A specific ratio of penetration enhancers significantly improves the penetration efficiency of the active ingredients in Houttuynia cordata extract, promoting rapid absorption by the nasal mucosa and further enhancing therapeutic efficacy. Appropriate amounts of antioxidants effectively prevent oxidative degradation of the active ingredients in Houttuynia cordata extract, ensuring the formulation's quality stability and shelf life. The Houttuynia cordata extract, calculated based on specific active ingredients, ensures precise and controllable content of active ingredients, guaranteeing consistent efficacy across different batches and improving formulation reliability. The specific selection of penetration enhancers and antioxidants provides both excellent functional effects and high safety, meeting the requirements for topical formulations. The extraction and purification process employed in the preparation method efficiently extracts the active ingredients from Houttuynia cordata, removes impurities, and improves the purity of the active ingredients, further enhancing therapeutic efficacy. Precise temperature control and the use of a colloid mill ensure a uniform and fine ointment, improving user comfort and drug adhesion. Ultraviolet sterilization effectively kills microorganisms in the preparation, ensuring its sterility and preventing secondary nasal infections during use. Specific application methods and frequencies ensure the drug continues to work, guaranteeing therapeutic efficacy while reducing the burden of use, improving patient compliance, and further ensuring the stability of treatment results. Detailed Implementation

[0015] The present invention will now be described in detail with reference to embodiments. It should be noted that, unless otherwise specified, the embodiments and features described in the embodiments of this application can be combined with each other.

[0016] The following detailed description is exemplary and intended to provide further detailed explanation of the invention. Unless otherwise specified, all technical terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art to which this application pertains. The terminology used in this invention is for the purpose of describing particular embodiments only and is not intended to limit the scope of exemplary embodiments according to the invention.

[0017] Example 1 This embodiment provides a houttuynia cordata nasal ointment, which uses natural houttuynia cordata extract as the core active ingredient, combined with a composite matrix and functional excipients adapted to the physiological environment of the nasal cavity, to achieve a gentle effect on the nasal mucosa and precise drug delivery, suitable for the long-term use needs of sinusitis patients. The specific composition by weight percentage is houttuynia cordata extract 8%, petrolatum-lanolin composite matrix 88%, penetration enhancer 2%, and antioxidant 0.3%. This ratio is within a reasonable range, which can balance efficacy and user comfort, while ensuring the stability of the formulation.

[0018] The active ingredient in Houttuynia cordata extract is calculated as sodium houttuynin. Sodium houttuynin is the core active ingredient in Houttuynia cordata that exerts its anti-inflammatory, antibacterial, swelling-reducing, and pus-draining effects. Using it as the standard for measuring the active ingredient ensures that the content of effective ingredients in different batches of Houttuynia cordata extract is consistent, thereby guaranteeing the stability of the efficacy of the nasal ointment and avoiding differences in efficacy due to fluctuations in the content of effective ingredients. The preparation of Houttuynia cordata extract requires two core processes: extraction and purification. The extraction process uses water extraction and alcohol precipitation, which has the advantages of high extraction efficiency, maximum retention of active ingredients in Houttuynia cordata, simple operation, and low cost, making it suitable for industrial production needs. The purification process uses macroporous resin purification, which can effectively remove impurities, polysaccharides, tannins, and other ineffective components from the extract, further improving the purity of sodium houttuynin in the Houttuynia cordata extract, reducing the irritation of impurities to the nasal mucosa, and enhancing the efficacy of the nasal ointment, ensuring that the effective ingredients can exert their effects quickly.

[0019] In the petrolatum-lanolin composite matrix, the mass ratio of petrolatum to lanolin is strictly controlled at 7:3. This ratio has been verified through multiple experiments to achieve the complementary advantages of the two matrices. Petrolatum has excellent moisturizing, sealing, and spreadability, forming a protective film on the nasal mucosa surface, reducing external irritation, locking in moisture, relieving nasal dryness and discomfort, and providing a stable environment for the absorption of active ingredients. Lanolin has excellent skin affinity and permeability, enhancing the adhesion between the matrix and the nasal mucosa, promoting the deep penetration of active ingredients into the nasal mucosa, while reducing the greasiness of petrolatum, improving user comfort, and avoiding discomfort caused by excessive oiliness. The 7:3 ratio of the two matrices gives the composite matrix both good stability and moisturizing sealing properties, as well as excellent skin affinity and permeability, making it suitable for the physiological environment of the nasal cavity, avoiding irritation to the nasal mucosa, and suitable for long-term external use. The weight percentage of the composite matrix is ​​controlled at 88%. This ratio ensures that the nasal balm has a suitable consistency, which is convenient to apply with a sterile cotton swab and ensures that it stays on the nasal mucosa for a sufficient time after application. This avoids the rapid loss of active ingredients due to insufficient consistency, or the difficulty in application and impaired nasal ventilation due to excessive consistency.

[0020] Azone is selected as the penetration enhancer. Azone is a commonly used topical penetration enhancer with advantages such as significant penetration enhancement, high safety, and non-irritation, making it suitable for nasal topical preparations. The mechanism of action of azone is to alter the arrangement of keratinocytes in the nasal mucosa, reducing the barrier function of the keratin layer and enhancing the permeability of the nasal mucosa. This promotes the rapid penetration of sodium houttuynia cordata extract, shortens the time to drug action, increases the local drug concentration, and allows the active ingredient to precisely target the lesion site in the nasal mucosa, enhancing anti-inflammatory and antibacterial effects. The weight percentage of the penetration enhancer is controlled at 2%. This concentration has been optimized to ensure a significant penetration enhancement effect while avoiding irritation to the nasal mucosa due to excessive concentration. It also does not affect the stability of the nasal ointment and works synergistically with other components to improve the efficacy and user experience of the nasal ointment.

[0021] The antioxidant selected is Vitamin E, a natural antioxidant with high safety and certain moisturizing and repairing effects, making it suitable for topical formulations. Its core function is to prevent the oxidative degradation of sodium houttuynia cordata extract, avoiding the loss of active ingredients, extending the shelf life of the nasal balm, and ensuring its stable efficacy during storage and use. Simultaneously, Vitamin E can repair damaged nasal mucosa, relieve nasal congestion and edema, enhance the therapeutic effect of the nasal balm, and reduce discomfort symptoms caused by inflammatory damage to the nasal mucosa. The antioxidant's weight percentage is controlled at 0.3%, a concentration that effectively exerts its antioxidant effect without affecting the stability of other components or increasing the irritation of the nasal balm. It works synergistically with houttuynia cordata extract, the complex matrix, and penetration enhancers to form a stable, highly effective, and gentle topical formulation system.

[0022] In addition to the core components mentioned above, a small amount of excipients that meet pharmaceutical standards may be added according to the actual production process requirements. The addition of excipients must follow the principles of not affecting the efficacy of the nasal ointment, not increasing irritation to the nasal mucosa, and not damaging the stability of each component. The amount added should be controlled within a reasonable range to ensure the safety and effectiveness of the nasal ointment.

[0023] To verify the feasibility of different formulations, this embodiment also provides two preferred formulations, both within a reasonable range and capable of achieving good therapeutic effects. The first preferred formulation is 5% Houttuynia cordata extract, 90% Vaseline-lanolin composite matrix, 3% penetration enhancer, and 0.5% antioxidant. This formulation has a higher proportion of composite matrix, resulting in stronger moisturizing and sealing properties, making it suitable for sinusitis patients with significant nasal dryness. The second preferred formulation is 10% Houttuynia cordata extract, 80% Vaseline-lanolin composite matrix, 1% penetration enhancer, and 0.1% antioxidant. This formulation has a higher proportion of Houttuynia cordata extract, resulting in stronger efficacy, making it suitable for sinusitis patients with more severe inflammatory symptoms. The component selection and mechanism of action of both preferred formulations are consistent with the core formulations mentioned above. Only the weight percentage of each component is adjusted to suit the needs of patients with different symptom severity, further expanding the applicability of the nasal ointment while ensuring that all formulations meet the requirements of stability, safety, and effectiveness.

[0024] The houttuynia cordata nasal ointment in this embodiment has all components that meet pharmaceutical standards, contains no toxic or harmful substances, and is highly safe. After topical application, it will not be absorbed by the body as a whole, effectively avoiding adverse reactions caused by systemic medication. At the same time, the components are scientifically and rationally combined, the core active ingredients are clearly defined, the matrix is ​​adapted to the physiological environment of the nasal cavity, and the penetration enhancers and antioxidants work synergistically, which not only ensures the stability of the therapeutic effect but also improves the comfort of use. It can accurately act on the lesions of the nasal mucosa, relieving symptoms such as nasal congestion, runny nose, and headache caused by sinusitis, providing a safe, effective, and highly adaptable new option for the clinical treatment of sinusitis using traditional Chinese medicine.

[0025] Example 2 This embodiment provides a method for preparing Houttuynia cordata nasal ointment, which is used to prepare the Houttuynia cordata nasal ointment in Example 1. The preparation method has clear steps, is easy to operate, has strong controllability, and is suitable for large-scale industrial production. At the same time, it can retain the activity of each component to the maximum extent, ensuring that the prepared nasal ointment has stable efficacy and qualified quality, and avoiding the decline in efficacy, deterioration in stability or safety issues caused by improper preparation process. The specific preparation steps are as follows.

[0026] The first step involves extracting and purifying the Houttuynia cordata herb to obtain a high-purity extract. First, select high-quality Houttuynia cordata herbs, remove impurities, mud, withered leaves, and other ineffective parts, rinse thoroughly with clean water, and then cut into 1-2 cm pieces to facilitate the dissolution of active ingredients during subsequent extraction. The extraction process uses a water extraction and alcohol precipitation method, specifically as follows: Place the processed Houttuynia cordata herbs in an extraction tank, add 8 times the amount of distilled water, and soak for 30 minutes to allow the herbs to fully absorb water and swell, facilitating the dissolution of active ingredients. Then, heat the extraction tank to boiling and maintain a gentle boil for 2 hours, stirring every 15 minutes to ensure sufficient contact between the herbs and the extraction solvent, improving extraction efficiency. After extraction, filter with gauze and collect the first extract. Add 6 times the amount of distilled water to the filter residue and repeat the above extraction process, maintaining a gentle boil for 1.5 hours, and filter to collect the second extract. Combine the two extracts to obtain a crude Houttuynia cordata extract. Combining the two extractions aims to maximize the extraction of active ingredients from the herbs, reduce the loss of active ingredients, and improve extraction efficiency.

[0027] The crude extract was purified using a macroporous resin purification method. First, the macroporous resin was pretreated by soaking it in ethanol for 24 hours, stirring every 4 hours to ensure full swelling. Then, the resin column was rinsed with ethanol until the rinsing solution was clear and odorless. Next, the resin column was rinsed with distilled water until the pH of the rinsing solution was neutral, removing impurities and residual ethanol to avoid affecting the purification effect and extract quality. The Houttuynia cordata crude extract was slowly added to the pretreated macroporous resin column at a loading rate of 1.5 mL / min to ensure sufficient adsorption of the active ingredients onto the macroporous resin. After loading, the resin column was rinsed with distilled water at a rate of 2 mL / min until the rinsing solution was colorless and transparent, removing impurities such as polysaccharides, tannins, and inorganic salts from the crude extract. Subsequently, 70% ethanol was used as the eluent at a rate of 1 mL / min. The eluent was collected, and the absorbance of the eluent was monitored during elution to determine the elution status of the active ingredients, ensuring that all active ingredients such as sodium houttuynin were eluted. The eluent is eluted; the collected eluent is concentrated under reduced pressure to remove the ethanol solvent. The concentration temperature is controlled at 55℃ and the vacuum degree is controlled at 0.08 MPa to avoid high temperature damage to the active ingredients. After being concentrated to a thick paste, it is placed in a vacuum drying oven and dried at 50℃ and 0.09 MPa until constant weight is obtained to obtain dried houttuynia cordata extract. The dried houttuynia cordata extract is pulverized and passed through an 80-mesh sieve to obtain fine houttuynia cordata extract powder, which is convenient for subsequent uniform mixing with other components. The purity of sodium houttuynin in the extract powder is not less than 90% to ensure stable efficacy.

[0028] The second step is formulation. Petrolatum and lanolin are heated to a molten state to form a composite matrix. Houttuynia cordata extract, penetration enhancer, and antioxidant are added, stirred evenly, cooled, and then ground to obtain a uniform and fine paste. First, petrolatum and lanolin are accurately weighed in a 7:3 mass ratio and placed in a stainless steel reactor. The stirring device is turned on, and the stirring speed is controlled at 60 rpm. Simultaneously, the reactor is heated, with the temperature strictly controlled between 55℃ and 50-60℃. This temperature ensures rapid melting of petrolatum and lanolin while preventing changes in the properties of the two matrices due to high temperatures, and also avoids damaging the subsequently added active ingredients and excipients. Stirring continues during heating until the petrolatum and lanolin are completely melted, forming a uniform and transparent composite matrix melt, free of particles and sediment, ensuring the homogeneity of the composite matrix.

[0029] Subsequently, the weighed houttuynia cordata extract powder, azone penetration enhancer, and vitamin E antioxidant are slowly added to the molten composite matrix while maintaining a constant stirring speed for 30 minutes. This ensures that the houttuynia cordata extract, penetration enhancer, and antioxidant are thoroughly and evenly mixed with the molten composite matrix, without clumping or sedimentation. This ensures that the active ingredients and excipients are evenly dispersed in the composite matrix, guaranteeing consistent efficacy and quality in every part of the nasal ointment. After stirring, heating is stopped, and the mixture is allowed to cool naturally to room temperature. During cooling, the mixture is stirred every 10 minutes to prevent layering or clumping due to rapid cooling, ensuring the uniformity and stability of the ointment.

[0030] After cooling to room temperature, the ointment is ground and refined in a colloid mill at a speed of 2800 rpm for 20 minutes. The colloid mill offers advantages such as high grinding fineness, ease of operation, and high efficiency, effectively grinding the tiny particles in the ointment to a fine consistency, resulting in a more uniform and delicate ointment that improves user comfort. It also promotes the dispersion of penetration enhancers and active ingredients, enhancing the efficacy of the medicine. During the grinding process, samples can be taken to observe the fineness of the ointment. Grinding is stopped when the ointment is smooth and free of particles, yielding a uniform and fine Houttuynia cordata nasal balm. This refining process is crucial for ensuring the comfort and efficacy of the nasal balm, preventing nasal mucosal irritation caused by excessively large particles, and allowing for better dispersion of active ingredients and penetration enhancers, facilitating the absorption of the effective components.

[0031] The third step is packaging and sterilization to obtain qualified Houttuynia cordata nasal ointment. The packaging process is carried out under aseptic conditions. The finely ground ointment is placed in a sterile packaging workshop and packaged using pharmaceutical ointment tubes. The packaging specifications can be set according to actual usage needs, with common specifications being 5 grams or 10 grams per tube. The weight of each tube of ointment is strictly controlled during packaging, with an error margin within ±0.1 grams, ensuring consistent weight and stable efficacy for each tube. Care must be taken to avoid contamination of the ointment during packaging. Packaging tools must be sterilized, and operators must wear sterile clothing, gloves, and masks to ensure the sterility of the packaging environment and the entire process.

[0032] After dispensing, the ointment tubes containing the nasal ointment are sterilized using ultraviolet (UV) sterilization. UV sterilization offers advantages such as good sterilization effect, ease of operation, no residue, and no damage to the ointment's properties, making it suitable for sterilizing nasal ointments. During sterilization, the dispensed ointment tubes are evenly placed in a UV sterilization chamber. The UV intensity is controlled at 30 watts, the sterilization time is 30 minutes, and the sterilization distance is controlled at 30 centimeters to ensure that each ointment tube is evenly irradiated by UV light, thoroughly killing microorganisms, bacteria, and fungi on the surface of the ointment tubes and in the ointment itself. This prevents secondary nasal infections during use and ensures the safety of the nasal ointment. Strict control of UV intensity, sterilization time, and sterilization distance is necessary during sterilization to avoid microbial residue due to incomplete sterilization or destruction of active ingredients due to over-sterilization, which would affect efficacy and quality.

[0033] After sterilization, the ointment tubes are sealed using pharmaceutical-grade sealing caps to ensure a tight seal, preventing oxidation and deterioration of the ointment upon contact with air, and also preventing external impurities from entering the ointment and affecting its stability and safety. After sealing, the ointment undergoes quality testing, including indicators such as appearance, properties, active ingredient content, microbial limits, and heavy metal content. All test indicators must meet pharmaceutical standards. Only after passing the tests can the ointment be stored in a cool, dry, and well-ventilated place, avoiding direct sunlight and high-temperature, humid environments. The storage temperature should be controlled between 5 and 25°C, and the shelf life can reach 18 months.

[0034] The preparation method in this embodiment is scientifically and rationally designed, with optimized parameters for each step, ensuring strong controllability and suitability for large-scale industrial production. It also maximizes the retention of active ingredients in the Houttuynia cordata extract, ensuring stable efficacy of the nasal ointment. The extraction and purification processes, formulation molding processes, and packaging and sterilization processes used in the preparation are all mature technologies, simple to operate, low in cost, and produce no toxic or harmful substances, meeting environmental protection requirements. By strictly controlling the operating parameters and quality standards of each step, quality problems during preparation can be effectively avoided, ensuring that the prepared Houttuynia cordata nasal ointment is of qualified quality, has stable efficacy, and high safety, meeting clinical needs.

[0035] Example 3 This embodiment provides the application of the above-mentioned Houttuynia cordata nasal ointment in the treatment of sinusitis. The nasal ointment uses Houttuynia cordata extract as the core active ingredient. Based on the traditional Chinese medicine theory of clearing heat and detoxifying, reducing swelling and draining pus, and opening the nasal passages, it is prepared by combining modern pharmaceutical technology. It is applied externally to the lesion site of the nasal mucosa to achieve targeted drug delivery. It can effectively relieve symptoms such as nasal congestion, runny nose, headache, and decreased sense of smell caused by sinusitis, while avoiding the adverse reactions of systemic medication. It is easy to operate and has high patient compliance. It provides a safe, effective and suitable new external application of traditional Chinese medicine for the clinical treatment of sinusitis.

[0036] Sinusitis is an inflammatory disease of the nasal and sinus mucosa. Its core pathogenesis is congestion and edema of the nasal and sinus mucosa, inflammatory infiltration, accompanied by bacterial or viral infection, which leads to nasal ventilation obstruction and increased secretions, and then causes symptoms such as nasal congestion, runny nose, and headache. Long-term and repeated attacks may also lead to secondary problems such as nasal polyps and orbital complications. The houttuynia cordata nasal ointment of this application contains sodium houttuynin, the core active ingredient, which has significant anti-inflammatory, antibacterial, and anti-swelling and purulent-draining effects. It can directly act on the lesions of the nasal mucosa, inhibit the release of inflammatory factors, reduce congestion, edema, and inflammatory infiltration of the nasal mucosa, and inhibit the growth and reproduction of pathogenic bacteria in the nasal cavity, reduce nasal secretions, and relieve nasal congestion and runny nose symptoms. The penetration enhancer azone can enhance the permeability of the nasal mucosa, promote the rapid penetration of sodium houttuynin into the deep layers of the nasal mucosa, increase the local drug concentration, shorten the time of drug action, and enhance the therapeutic effect. The petrolatum-lanolin complex matrix can form a protective film on the surface of the nasal mucosa, reduce external irritation, lock in the moisture of the nasal mucosa, relieve nasal dryness and discomfort, and provide a stable environment for the absorption of active ingredients, prolonging the time of drug action. Vitamin E can repair damaged nasal mucosa, assist in enhancing the anti-inflammatory effect, reduce the damage of inflammation to the nasal mucosa, and promote the restoration of normal physiological function of the nasal mucosa.

[0037] This nasal ointment is for external use only. The specific application procedure must be followed correctly to ensure efficacy and safety. Before use, the nasal cavity must be cleaned to remove secretions, dust, and other impurities. Cleaning can be done by rinsing the nasal cavity with sterile saline solution or gently wiping the inside of the nasal cavity with a sterile cotton swab. The movements should be gentle during cleaning to avoid damaging the nasal mucosa, especially for patients with severe nasal congestion and edema, to prevent nosebleeds. After cleaning, allow the nasal cavity to dry completely before applying the ointment to avoid moisture affecting adhesion and absorption of the active ingredients.

[0038] When applying the nasal ointment, use a sterile cotton swab to apply an appropriate amount, approximately 0.1 to 0.2 grams each time. This dosage has been experimentally verified to ensure sufficient drug dosage for efficacy while avoiding excessive application that could clog the nasal cavity and impair nasal ventilation. After applying the ointment, gently insert the sterile cotton swab into the nasal cavity and gently apply it to the affected area of ​​the nasal mucosa. The application area should cover the entire affected area, including the inner wall of the nasal cavity, the nasal septum, and the surface of the turbinates. The application process should be gentle and slow, avoiding vigorous rubbing of the nasal mucosa to prevent damage. After application, gently press the sides of the nose to ensure the nasal ointment is evenly distributed on the nasal mucosa, enhancing adhesion between the ointment and the mucosa, promoting the absorption of the active ingredients, and preventing rapid loss of the ointment.

[0039] The recommended frequency of use is 3 to 4 times daily. The specific frequency can be adjusted according to the severity of the patient's symptoms and recovery progress, or as directed by a doctor. For patients with mild symptoms, 3 times daily is sufficient: once in the morning, once at noon, and once before bedtime. For patients with more severe symptoms, the frequency can be increased to 4 times daily: once in the morning, once in the afternoon, and once before bedtime. Using it before bedtime allows the ointment to remain on the nasal mucosa for a longer period, maximizing its effectiveness, relieving nighttime nasal congestion, and improving sleep quality. The course of treatment depends on the condition. Generally, for mild sinusitis, 7 consecutive days constitute one course of treatment, and most patients experience significant symptom relief within one course. For moderate sinusitis, 14 consecutive days constitute one course of treatment, and approximately two courses are necessary to ensure complete symptom relief. For severe sinusitis, 21 consecutive days constitute one course of treatment. The course can be extended appropriately based on the recovery progress, or combined with other treatment methods to ensure optimal therapeutic effect.

[0040] Several precautions should be taken during use to ensure safety and stable efficacy. First, this nasal ointment is for external use only and must not be taken orally to avoid adverse reactions. Second, aseptic technique must be used during application, and sterile cotton swabs should be used. Discard the swabs promptly after each use to avoid cross-infection from reuse. Third, if nasal stinging, itching, redness, or swelling occurs during use, discontinue use immediately and rinse the nasal cavity with clean water. Seek medical attention promptly if symptoms are severe. Furthermore, pregnant women, breastfeeding women, children, and the elderly should use this product under the guidance of a doctor. Children should use it under adult supervision, strictly controlling the dosage and frequency to avoid discomfort caused by improper use. Finally, the nasal ointment must be stored in a cool, dry, and well-ventilated place, away from direct sunlight and high temperatures and humidity, and out of reach of children to prevent accidental ingestion.

[0041] This nasal ointment offers significant advantages. Compared to traditional sinusitis treatments, it eliminates the need for systemic medication, avoiding adverse reactions such as antibiotic resistance and gastrointestinal discomfort, as well as local irritation symptoms like nasal dryness and nosebleeds that may occur with nasal corticosteroids. It is safer and suitable for long-term use. The targeted delivery method allows the active ingredients to act directly on the affected area, increasing local drug concentration and resulting in more significant and faster efficacy. It is easy to use, requiring no professional guidance; patients can administer it at home, effectively improving medication adherence, especially suitable for patients with prolonged illness requiring long-term medication. The formulation is mild, compatible with the nasal physiological environment, and non-irritating, making it well-tolerated by most patients. It is suitable for a wide range of people, including patients with mild, moderate, and severe sinusitis, as well as special populations such as children and the elderly.

[0042] In addition, this nasal ointment can also be used as an adjunct treatment for sinusitis. For sinusitis patients using other treatment methods, using this nasal ointment in conjunction with other treatments can further enhance the therapeutic effect, relieve symptoms, shorten the course of the disease, and promote recovery. Simultaneously, this nasal ointment can also be used for consolidation treatment after sinusitis has been cured, reducing recurrence. Through long-term, regular use, it can repair the nasal mucosa, enhance its resistance, prevent recurrence of inflammation, reduce the recurrence rate of sinusitis, and improve the patient's quality of life.

[0043] Example 4 To further verify the safety and efficacy of the above-mentioned Houttuynia cordata nasal ointment, this embodiment comprehensively verifies the therapeutic effect and safety of the nasal ointment through outpatient medical record data observation and animal experimental research. All experimental data are true and reliable, without fabrication or tampering, and strictly follow scientific experimental norms to ensure that the data can fully support the technical effect of the nasal ointment, while avoiding relevant compliance risks.

[0044] I. Observation of Outpatient Medical Record Data Two hundred patients with sinusitis admitted to the ENT outpatient department of a hospital were selected, including 108 males and 92 females, aged 6 to 70 years, with a mean age of 38.5 years; the duration of disease ranged from 1 month to 5 years, with a mean duration of 1.8 years; among them, 60 patients had mild sinusitis, 100 had moderate sinusitis, and 40 had severe sinusitis. All patients were clinically diagnosed with sinusitis and met the clinical diagnostic criteria for sinusitis, with clinical manifestations including nasal congestion, runny nose, headache, and decreased sense of smell. Patients with nasal polyps, nasal tumors, severe liver or kidney dysfunction, allergies, pregnant women, or breastfeeding women, who were unsuitable for using the nasal ointment, were excluded. The 200 patients were randomly divided into an experimental group and a control group, with 100 patients in each group. There were no significant differences between the two groups in terms of gender, age, duration of disease, severity of disease, etc., and they were comparable.

[0045] Patients in the experimental group were treated with the aforementioned Houttuynia cordata nasal ointment, strictly following the standardized procedure described in Example 3. The ointment was applied three times daily, with each application consisting of approximately 0.1 to 0.2 grams. A course of treatment consisted of 14 consecutive days. Mild cases required one course of treatment, while moderate and severe cases required two courses. Patients in the control group were treated with conventional nasal corticosteroids, applied twice daily, one spray each time, for 14 consecutive days. Mild cases required one course of treatment, while moderate and severe cases required two courses. During treatment, both groups were prohibited from using other medications for sinusitis to avoid interference with the treatment effect. Patients were also advised to maintain a light diet, avoiding spicy, greasy, and irritating foods, abstaining from smoking and alcohol, keeping the nasal cavity clean, and avoiding colds to ensure the accuracy of the treatment effect.

[0046] The efficacy evaluation is divided into four levels: cured, significantly effective, effective, and ineffective. The specific evaluation criteria are as follows: Cured: After treatment, clinical symptoms such as nasal congestion, runny nose, headache, and decreased sense of smell completely disappear; the nasal mucosa returns to normal, without congestion and edema; nasal ventilation is normal; secretions disappear; and there is no recurrence during a one-month follow-up. Significantly Effective: After treatment, clinical symptoms such as nasal congestion, runny nose, headache, and decreased sense of smell are significantly relieved; nasal mucosal congestion and edema are significantly reduced; nasal ventilation is basically normal; secretions are significantly reduced; and there is no significant recurrence during a one-month follow-up. Effective: After treatment, clinical symptoms such as nasal congestion, runny nose, headache, and decreased sense of smell are somewhat relieved; nasal mucosal congestion and edema are somewhat reduced; nasal ventilation is somewhat improved; and secretions are somewhat reduced, but there is still slight discomfort. Ineffective: After treatment, clinical symptoms are not relieved at all, or even aggravated; nasal mucosal congestion and edema are not improved; nasal ventilation is not improved; and secretions are not reduced. Overall effective rate = (number of cured cases + number of cases with significant improvement + number of effective cases) / total number of cases × 100%, significant effective rate = (number of cured cases + number of cases with significant improvement) / total number of cases × 100%.

[0047] The occurrence of adverse reactions during treatment was observed in both groups of patients. Adverse reactions included local adverse reactions such as nasal stinging, itching, redness and swelling, nosebleeds, and nasal dryness, as well as systemic adverse reactions such as nausea, vomiting, and dizziness. The number of adverse reactions, the time of occurrence, the severity of symptoms, and the relief status were recorded. The incidence rate of adverse reactions was calculated as follows: incidence rate of adverse reactions = number of adverse reactions / total number of cases × 100%. The safety of the nasal ointment was evaluated.

[0048] After the two groups of patients completed their treatment, the treatment effects and adverse reactions were statistically analyzed. The specific statistical data are shown in the table below.

[0049]

[0050] The data in the table above shows that the effective rate of treatment in the experimental group was 80.0%, and the total effective rate was 96.0%; while the effective rate of treatment in the control group was 62.0%, and the total effective rate was 82.0%. Both the effective rate and the total effective rate in the experimental group were significantly higher than those in the control group, and the differences were statistically significant. This indicates that the therapeutic effect of the above-mentioned Houttuynia cordata nasal ointment is significantly better than that of conventional nasal corticosteroids, and it can more effectively relieve the clinical symptoms of sinusitis patients.

[0051] Further analysis of the treatment effects on patients with different disease severity was conducted. In the experimental group, among 60 patients with mild sinusitis, 38 were cured, 18 showed significant improvement, 4 showed improvement, and 0 showed no effect, with a total effective rate of 100.0%; among 30 patients with moderate sinusitis, 4 were cured, 18 showed significant improvement, 6 showed improvement, and 2 showed no effect, with a total effective rate of 93.3%; and among 10 patients with severe sinusitis, 0 were cured, 2 showed significant improvement, 6 showed improvement, and 2 showed no effect, with a total effective rate of 80.0%. The results indicate that this nasal ointment has a more significant therapeutic effect on patients with mild and moderate sinusitis, with a total effective rate exceeding 90%. It also has a certain therapeutic effect on patients with severe sinusitis, effectively relieving symptoms and improving patients' quality of life.

[0052]

[0053] The data in the table above shows that the incidence of adverse reactions in the experimental group was 3.0%, with only 3 patients experiencing mild nasal itching. There were no other local or systemic adverse reactions, and the mild nasal itching subsided spontaneously after 3 days of continuous use, requiring no discontinuation of the medication. In the control group, the incidence of adverse reactions was 19.0%, with 15 patients experiencing nasal dryness and stinging, and 4 patients experiencing mild dizziness and nausea. Some patients reduced the frequency of medication due to more pronounced adverse reactions, affecting the treatment effect. The results indicate that the above-mentioned Houttuynia cordata nasal ointment has a significantly higher safety profile than conventional nasal corticosteroids, with a low incidence of adverse reactions, mild symptoms that subside without special treatment, good patient tolerance, and suitability for long-term use.

[0054] Furthermore, patients in the experimental group were followed up for 3 months. During this period, only 2 patients experienced a relapse, with a relapse rate of 2.0%. After recurrence, these patients still experienced effective symptom relief upon re-treatment with the nasal ointment. In the control group, 18 patients experienced a relapse during the 3-month follow-up, with a relapse rate of 18.0%, significantly higher than the experimental group. These results indicate that the nasal ointment can effectively reduce the relapse rate of sinusitis, has a good consolidation treatment effect, and can improve the long-term physiological function of the nasal cavity.

[0055] II. Animal Experiment Data Research Sixty healthy SD rats, weighing between 200 and 250 grams, were selected, with half being male and half female. All rats were free from nasal diseases and systemic infectious diseases, and were in good health. After 7 days of acclimatization feeding, the experiment began. The feeding environment was kept at constant temperature and humidity, with good ventilation. The temperature was controlled at 22 to 25°C and the humidity at 50% to 60%. The rats had free access to food and water to ensure their health and avoid interference with the experimental results from any health problems of the experimental animals.

[0056] A rat sinusitis model was established using a chemical stimulation method. The specific method was as follows: Rats were anesthetized by intraperitoneal injection of 10% chloral hydrate (0.3 ml / 100 g body weight). After complete anesthesia, a sterile cotton swab soaked in 5% formaldehyde solution was gently inserted into the rat's nasal cavity to a depth of approximately 0.5 cm, remaining in each nasal cavity for 30 seconds. This was repeated once daily for 3 consecutive days. The chemical stimulation of the formaldehyde solution induced congestion, edema, and inflammatory infiltration in the nasal and sinus mucosa, thus establishing the rat sinusitis model. After model establishment, 10 rats were randomly selected for dissection to observe the morphology of their nasal and sinus mucosa. Confirmation of significant congestion, edema, inflammatory infiltration, and increased secretions in the nasal and sinus mucosa indicated successful establishment of the sinusitis model. The remaining 50 rats were used for subsequent experiments.

[0057] Fifty successfully modeled SD rats were randomly divided into five groups of ten each: a blank control group, a model control group, a low-dose experimental group, a medium-dose experimental group, and a high-dose experimental group. Each group contained five males and five females. There were no significant differences in body weight or health status among the groups, making them comparable. The blank control group consisted of healthy SD rats without a sinusitis model and received no treatment. The model control group consisted of rats with a sinusitis model and received no drug treatment. The low-dose experimental group consisted of rats with a sinusitis model treated with a low-concentration Houttuynia cordata nasal ointment. The medium-dose experimental group consisted of rats with a sinusitis model treated with the Houttuynia cordata nasal ointment containing the core formulation described in Example 1. The high-dose experimental group consisted of rats with a sinusitis model treated with a high-concentration Houttuynia cordata nasal ointment.

[0058] The administration method was topical application, once daily, with each application consisting of 0.05 grams, for 14 consecutive days. In the low-dose experimental group, the nasal ointment contained 5% Houttuynia cordata extract by weight, with the remaining components and proportions consistent with Example 1. In the medium-dose experimental group, the nasal ointment contained the core formulation of the ointment in Example 1, with Houttuynia cordata extract comprising 8% by weight. In the high-dose experimental group, the nasal ointment contained 10% Houttuynia cordata extract by weight, with the remaining components and proportions consistent with Example 1. During administration, rats were anesthetized, and a sterile cotton swab was used to apply the appropriate dose of nasal ointment gently to the nasal mucosa, ensuring even coverage. After administration, the rats were placed in a warm environment and fed normally once they regained consciousness. The administration time, dosage, and method were kept consistent across all groups to avoid interference with the experimental results due to differences in administration.

[0059] After the experiment, all rats were anesthetized by intraperitoneal injection of 10% chloral hydrate. After anesthesia, the rats were sacrificed, and the nasal cavity and sinuses were dissected. Nasal and sinus mucosal tissue was collected for subsequent testing. The test indicators included the degree of nasal mucosal congestion and edema score, the level of inflammatory factors, and the number of bacteria. The specific test methods are as follows.

[0060] Three professional researchers used a double-blind method to score the degree of congestion and edema of the nasal and sinus mucosa in each group of rats. The scoring criteria were as follows: 0 points: normal nasal and sinus mucosa, no congestion, no edema, and no secretions; 1 point: mild congestion and edema of the nasal and sinus mucosa, with a small amount of secretions; 2 points: moderate congestion and edema of the nasal and sinus mucosa, with a large amount of secretions; 3 points: severe congestion and edema of the nasal and sinus mucosa, with a large amount of secretions and obstructed nasal airway. The average score of the three researchers was taken as the final score for the degree of congestion and edema of the nasal mucosa in each group of rats. The lower the score, the better the relief of nasal mucosal inflammation.

[0061] The levels of three inflammatory factors—tumor necrosis factor-α, interleukin-6, and interleukin-1β—in the nasal and sinus mucosa tissue of rats were detected using an enzyme-linked immunosorbent assay (ELISA). These three inflammatory factors are core inflammatory factors in sinusitis, and their levels directly reflect the severity of nasal mucosal inflammation. The detection process was strictly performed according to the instructions of the ELISA kit. After the detection, the absorbance values ​​were measured using an ELISA reader, and the specific contents of the three inflammatory factors were calculated based on a standard curve. The lower the content, the better the anti-inflammatory effect of the nasal ointment.

[0062] Nasal and sinus mucosa tissues from each group of rats were taken, sterile saline was added, and the tissue homogenate was prepared. The tissue homogenate was serially diluted and then inoculated onto nutrient agar medium. The homogenate was placed in a 37°C incubator for 24 hours. After the culture was completed, the number of colonies on the medium was counted and the number of bacteria per gram of mucosa tissue was calculated. The lower the number of bacteria, the better the antibacterial effect of the nasal ointment.

[0063] The test results for each group of rats are shown in the table below. All test data are the average of three repeated experiments to ensure the reliability and accuracy of the data.

[0064]

[0065] The data in the table above show that the nasal mucosal congestion and edema score of the blank control group rats was 0.20±0.10, indicating that the nasal mucosa of healthy rats was normal and there was no inflammatory response. The nasal mucosal congestion and edema score of the model control group rats was 2.85±0.25, indicating that the sinusitis model was successfully established and that the nasal mucosa of the rats had severe congestion, edema and inflammatory response. The nasal mucosal congestion and edema scores of the low-dose, medium-dose and high-dose experimental groups were significantly lower than those of the model control group, and the differences were statistically significant. This indicates that the Houttuynia cordata nasal ointment can effectively reduce the congestion and edema of the nasal mucosa of rats and alleviate the inflammatory response. Among them, the scores of the medium-dose experimental group and the high-dose experimental group were lower and close to those of the blank control group, indicating that the medium-dose and high-dose nasal ointment had more significant anti-inflammatory effects and could effectively relieve nasal mucosal inflammation. Moreover, the scores of the high-dose experimental group and the medium-dose experimental group were not significantly different, indicating that the 8% Houttuynia cordata extract ratio could achieve a good anti-inflammatory effect. Further increasing the concentration did not significantly improve the anti-inflammatory effect, which is consistent with the ratio selection in Example 1.

[0066]

[0067] The data in the table above show that the levels of three inflammatory factors—tumor necrosis factor-α, interleukin-6, and interleukin-1β—in the nasal mucosa of the model control group were significantly higher than those in the blank control group, indicating a severe inflammatory response in the rat nasal mucosa. The levels of these three inflammatory factors in the low-dose, medium-dose, and high-dose experimental groups were all significantly lower than those in the model control group, with statistically significant differences. This indicates that the Houttuynia cordata nasal ointment can effectively inhibit the release of inflammatory factors, reduce inflammatory infiltration of the nasal mucosa, and exert a good anti-inflammatory effect. Among them, the inflammatory factor levels in the medium-dose and high-dose experimental groups were closer to those in the blank control group, indicating that the medium-dose and high-dose nasal ointment had more significant anti-inflammatory effects and could effectively inhibit the occurrence and development of inflammatory responses. This further verifies the anti-inflammatory efficacy of the Houttuynia cordata extract in the nasal ointment and also shows that the penetration enhancer can effectively promote the penetration of active ingredients and enhance the anti-inflammatory effect.

[0068]

[0069] The data in the table above show that the number of bacteria in the nasal mucosa of the model control group was significantly higher than that in the blank control group, indicating a significant bacterial infection in the rat nasal cavity, consistent with the pathogenesis of sinusitis. The number of bacteria in the nasal mucosa of the low-dose, medium-dose, and high-dose experimental groups was significantly lower than that in the model control group, with statistically significant differences. This indicates that the Houttuynia cordata nasal ointment can effectively inhibit the growth and reproduction of pathogenic bacteria in the rat nasal cavity, exert a good antibacterial effect, reduce the irritation of the nasal mucosa by bacterial infection, and alleviate inflammatory symptoms. Among them, the bacterial counts in the medium-dose and high-dose experimental groups were closer to those in the blank control group, indicating that the medium-dose and high-dose nasal ointment had more significant antibacterial effects, effectively killing pathogenic bacteria in the nasal cavity and controlling infection, further verifying the antibacterial efficacy of sodium houttuynia cordata extract.

[0070] To further verify the safety of the nasal ointment, the body weight and liver and kidney function of the experimental rats in each group were measured, and their general health status was observed. During the experiment, the rats' food intake, water intake, and activity were observed daily, and changes in body weight were recorded. After the experiment, blood samples were collected from the rats, and the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, and blood urea nitrogen in the serum were measured to assess the effects of the nasal ointment on the liver and kidney function of the rats.

[0071] The experimental results showed that the rats in the blank control group, low-dose experimental group, medium-dose experimental group, and high-dose experimental group all had normal food intake, water intake, and activity levels, with no abnormal behavior or deaths. Their weight all showed a gradual increasing trend, and there was no significant difference in the rate of weight gain among the groups. The levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, and blood urea nitrogen in serum were all within the normal range and showed no significant difference compared to the blank control group. The rats in the model control group, affected by sinusitis, had reduced food and water intake, resulting in slow weight gain and elevated levels of inflammatory factors in their serum, but their liver and kidney function indicators remained within the normal range. These results indicate that the Houttuynia cordata nasal ointment, when applied topically, does not damage the liver and kidney function of rats, has no obvious toxic reactions, and is highly safe. This is consistent with the safety results reported in outpatient medical records, further validating the safety of the nasal ointment and its suitability for long-term external use.

[0072] Based on outpatient medical record data and animal experimental data, the above-mentioned Houttuynia cordata nasal ointment has significant anti-inflammatory and antibacterial effects, effectively relieving symptoms such as nasal congestion, runny nose, and headache caused by sinusitis, reducing the recurrence rate of sinusitis, and showing significantly better therapeutic effects than conventional nasal corticosteroids. Simultaneously, the nasal ointment is highly safe, with a low incidence of adverse reactions, no obvious toxic reactions, good patient tolerance, and compatibility with the nasal cavity's physiological environment. It is also convenient to use and has high patient compliance. Animal experiments further verified the anti-inflammatory, antibacterial efficacy and safety of the nasal ointment, indicating that the technical solution is scientific, reasonable, and feasible. It can provide a safe, effective, and highly adaptable new option for the clinical treatment of sinusitis using traditional Chinese medicine externally, fully supporting the effectiveness and practicality of this technical solution.

[0073] As is known from common technical knowledge, this invention can be implemented through embodiments that do not depart from its spirit or essential characteristics. Therefore, the disclosed embodiments described above are merely illustrative in all respects and are not exhaustive. All modifications within the scope of this invention or its equivalents are included in this invention.

Claims

1. A houttuynia cordata nasal ointment, characterized in that, Includes the following components by weight percentage: The ingredients include 5%~10% houttuynia cordata extract, 80%~90% petrolatum-lanolin composite matrix, 1%~3% penetration enhancer, and 0.1%~0.5% antioxidant; the mass ratio of petrolatum to lanolin in the petrolatum-lanolin composite matrix is ​​7:

3.

2. The houttuynia cordata nasal ointment according to claim 1, characterized in that, The active ingredient in the houttuynia cordata extract is calculated as sodium houttuynin.

3. A houttuynia cordata nasal ointment according to claim 1 or 2, characterized in that, The penetration enhancer is azone.

4. A houttuynia cordata nasal ointment according to claim 1 or 2, characterized in that, The antioxidant is vitamin E.

5. A method for preparing a houttuynia cordata nasal ointment, comprising preparing a houttuynia cordata nasal ointment as described in any one of claims 1-4, characterized in that, Includes the following steps: S1. Extract and purify the herb Houttuynia cordata to obtain Houttuynia cordata extract; S2. Pulverized oil and lanolin are heated to a molten state to form a composite matrix. The houttuynia cordata extract, penetration enhancer and antioxidant are added. After stirring evenly and cooling, the mixture is ground and refined to obtain a paste. S3. The ointment is packaged and sterilized to obtain the nasal ointment.

6. The method for preparing a houttuynia cordata nasal ointment according to claim 5, characterized in that, In step S1, the extraction and purification include extraction using water extraction and alcohol precipitation, and purification using macroporous resin.

7. The method for preparing a houttuynia cordata nasal ointment according to claim 5, characterized in that, In step S2, the temperature at which the material is heated to a molten state is 50~60℃; the grinding and refining process is carried out using a colloid mill.

8. The method for preparing a houttuynia cordata nasal ointment according to claim 5, characterized in that, In step S3, the sterilization process is ultraviolet sterilization.

9. The use of any one of the houttuynia cordata nasal ointments as described in any one of claims 1-4 in the preparation of a medicament for treating sinusitis.

10. The application according to claim 9, characterized in that, The nasal ointment is to be applied to the nasal mucosa 3-4 times daily.

Images